Skip to main content
TipRanks
Go Ultimate75% OFF

Spyros Papapetropoulos Insider Profile

4 Followers

Spyros Papapetropoulos, President & CEO, Director at Neuphoria Therapeutics, holds ― shares in Neuphoria Therapeutics (Ticker: NEUP), holds 21.74K shares in Lipocine (Ticker: LPCN), holds 4.00K shares in Vigil Neuroscience Inc (Ticker: VIGL).

Spyros Papapetropoulos's Trading History

LPCN
Lipocine
Nov 28, 2022DirectorInformative Buy10.22K$37.17K
VIGL
Vigil Neuroscience Inc
Nov 22, 2022―Uninformative Buy567.00$32.20K
ADMS
Adamas Pharmaceuticals
Nov 24, 2021―Uninformative Sell―$0.00
NEUP
Neuphoria Therapeutics
―President & CEO, Director――

You May Also Like

Spyros Papapetropoulos insider profile FAQ

What is the percentage of profitable transactions made by Spyros Papapetropoulos?
The percentage of profitable transactions made by Spyros Papapetropoulos is 50%.
What is the average return per transaction made by Spyros Papapetropoulos?
The average return per transaction made by Spyros Papapetropoulos is 24.40%.
What stocks does Spyros Papapetropoulos hold?
Spyros Papapetropoulos holds: NEUP, ADMS, LPCN, VIGL stocks.
What was Spyros Papapetropoulos's most profitable transaction?
Spyros Papapetropoulos’s most profitable transaction was an Informative Buy of VIGL stock on May 4, 2022. The return on the trade was 116.90%.
What is Spyros Papapetropoulos's role in Neuphoria Therapeutics?
Spyros Papapetropoulos's role in Neuphoria Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.